Navigation Links
NanoLogix Announces Development of Multi-Well, Rapid Diagnostic Test Variant and Exhibits at the American Society for Microbiology General Meeting in San Francisco
Date:6/12/2012

HUBBARD, Ohio, June 13, 2012 /PRNewswire/ -- NanoLogix (OTC Markets:NNLX) announced today its R&D team in collaboration with University of Texas Health Science Center - Houston (UTHSC-Houston) researchers, are developing a multi-well, microplate reader variant of the company's BioNanoFilter (BNF) diagnostics for use in large volume laboratory environments.  Early analysis of the multi-well plates shows exceptionally fast live-threat results similar to the company's standard BNF technology.  Starting this week, the NanoLogix BNF and BioNanoPore (BNP) technology will be on exhibit at booth #841 at the 112th General Meeting of the American Society for Microbiology in San Francisco, June 16 – June 19.

(Photo:  http://photos.prnewswire.com/prnh/20120613/CL23734)

Research using NanoLogix technology from a recently completed clinical study will also be presented at the ASM General Meeting on June 17th.  Dr. Jonathan Faro of UTHSC-Houston will present the research, which focused on detection, identification, and determination of antibiotic sensitivity of Group B Streptococcus (GBS) during pregnancy.  Data showed NanoLogix diagnostics consistently provided results in a 4 to 6 hour window, dramatically shorter than standard culturing times of 48 to 72 hours.  The data and the associated clinical study narrative is currently being formatted for submission for peer-review publication, as well as to the US FDA for acceptance as a non-invasive diagnostic technology. 

"These are exciting times for NanoLogix," said CEO Bret Barnhizer.  "Our technology has the potential to dramatically affect the course of human health and events over the past eight months have greatly enhanced our position for the future."   

Rapid Live-Threat Tuberculosis Results

Recent R&D operations have also converged to dramatically enrich NanoLogix' bacteria and protozoa detection technology portfolio.

The detection for Tuberculosis (TB) utilizing NanoLogix' BNF and BioNanoPore (BNP) technologies has recently been completed by a major independent, third-party research laboratory.  Live-threat TB was detected with NanoLogix BNP technology in 4 to 5 days, as opposed to 21 to 84 days with standard culture.  TB was also detected and identified with the company's BNF technology in less than two hours.  Peer-reviewed publication and FDA submittal are in process for results from both BNP and BNF Tuberculosis research.

"We are thrilled to be dramatically cutting bacterial detection times from days to hours for many pathogens," said Barnhizer.  "Specifically, we have reduced wait times for TB from weeks to days, while protozoa detection times for Cryptosporidium, which is responsible for over 50 percent of waterborne illnesses, have been cut from weeks to hours.  At the same time, we have been able to accomplish these results with improved quality of detection."

About NanoLogix, Inc.

NanoLogix is a biotechnology company focused primarily on rapid diagnostics. Its products offer accelerated detection and identification of microorganisms. In addition to medical and homeland security applications, NanoLogix technology is applicable in pharmaceutical, industrial, veterinary and environmental testing. Patents granted to NanoLogix can be used in the areas of applied microbiology, soil microbiology, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics, and antibiotic sensitivity. For more information visit  www.nanologix.com.

Media Contact:
Lisa Ann Pinkerton
Technica Communications for NanoLogix
408-806-9626
lisaann@technicacommunications.com

Investor Contact:
Carol Surrena
NanoLogix, Inc.
330-534-0800
carol@nanologix.com

This press release contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

 


'/>"/>
SOURCE NanoLogix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. NanoLogix Instructs Third-Party to Prepare US FDA Submittals and is Granted US and Chinese Patents
2. NanoLogix Provides Testing and Operations Update
3. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
4. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
5. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
6. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
7. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
8. WuXi PharmaTech Announces Third-Quarter 2011 Results
9. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
10. Spherix Announces Third Quarter Financial Results
11. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... NY (PRWEB) , ... May 03, 2016 , ... According ... Hospital , for definitive prostate cancer treatment, patients traditionally had two main treatment options: ... treatment plan would be made. , New technology has enabled doctors to administer ...
(Date:5/2/2016)... , ... May 02, 2016 , ... StarNet Communications Corp, ... announced the addition of three Secure Remote Desktop modules to its flagship X-Win32 PC ... from Linux and Unix servers to the user’s PC over encrypted SSH. , Traditionally, ...
(Date:4/29/2016)... ... April 29, 2016 , ... Amendia, Inc., a ... procedures, today announced the completion of a significant transaction and partnership that positions ... customers and partners. Kohlberg & Company, L.L.C. (“Kohlberg”), a leading private equity ...
(Date:4/29/2016)... ... April 29, 2016 , ... Intelligent Implant Systems announced today ... via 510(k) for sale in the United States. These components expand the capabilities ... With one-level sales beginning in October of 2015, the company has seen significant ...
Breaking Biology Technology:
(Date:3/11/2016)... -- --> --> ... Market by Technology (Pattern Recognition), by Component (Hardware, Software, ... (On-Premises and Cloud), by Industry Vertical and by Region ... global market is expected to grow from USD 12.49 ... at a CAGR of 19.1%. , ...
(Date:3/9/2016)... This BCC Research report provides an overview ... Sequencing (RNA Seq) market for the years 2015, 2016 ... reagents, data analysis, and services. Use this ... market such as RNA-Sequencing tools and reagents, RNA-Sequencing data ... each segment and forecast their market growth, future trends ...
(Date:3/8/2016)...   Valencell , the leading innovator in ... secured $11M in Series D financing. The investment ... fund being launched by UAE-based financial services company ... TDF Ventures and WSJ Joshua Fund. Valencell plans ... growth and accelerate its pioneering innovation in accurate ...
Breaking Biology News(10 mins):